Key cost drivers of pharmaceutical clinical trials in the United States

@article{Sertkaya2016KeyCD,
  title={Key cost drivers of pharmaceutical clinical trials in the United States},
  author={Aylin Sertkaya and Hui-Hsing Wong and Amber Jessup and Trinidad Beleche},
  journal={Clinical Trials},
  year={2016},
  volume={13},
  pages={117 - 126}
}
Background: The increasing cost of clinical research has significant implications for public health, as it affects drug companies’ willingness to undertake clinical trials, which in turn limits patient access to novel treatments. [...] Key Method We evaluated per-study costs across therapeutic areas by aggregating detailed (per patient and per site) cost information. We also compared average expenditures on cost drivers with the use of weighted mean and standard deviation statistics. Results: Therapeutic area…Expand
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study
TLDR
The estimated costs of the pivotal clinical trials supporting the approval of 101 new therapeutic agents approved by the US Food and Drug Administration from 2015 to 2017 are a cross-sectional study of the likely costs of clinical trials to be conducted by contract research organisations. Expand
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016
TLDR
The highest-cost trials were those in which the new agent had to be proved to be noninferior with clinical benefit end points compared with an agent already available or those that required larger patient populations to achieve statistical power to document smaller treatment effects or accrue infrequently occurring end points. Expand
Funding of Clinical Trials and Reported Drug Efficacy∗
Clinical trials are a key determinant of drug approvals and also influence prescription decisions. In recent years, an increasing share of clinical trials have been funded by pharmaceutical firms, asExpand
Closing the cycle of innovation in healthcare in Europe
TLDR
It would appear reasonable that decision makers should get more involved in priority setting and funding also in the field of clinical research in order to provide further evidence needed for assessments, reassessments, and subsequent qualified decisions and resource allocations in health care. Expand
Efficient design of clinical trials and epidemiological research: is it possible?
TLDR
The changing landscape ofclinical research, and clinical trials in particular, is discussed, focusing on reasons for the increasing costs and inefficiencies, including excessively complex design, overly restrictive inclusion and exclusion criteria, burdensome regulations, excessive source-data verification, and concerns about the effect of clinical research conduct on workflow. Expand
Future of risk based monitoring in clinical trials
TLDR
The future of risk based approach towards managing clinical trials is going to be very different from what the authors see now with the changing landscape of drug development which includes novel therapies like gene therapy, remote/decentralized trials, growing use of wearable technologies, esource, electronic health record/electronic medical records interoperability, implementation of artificial intelligence and machine learning algorithms. Expand
Registry-based trials: a potential model for cost savings?
TLDR
A practical tool that investigators could use across disciplines to estimate the ranges of potential cost differences associated with implementing registry-based trials versus standard clinical trials is built. Expand
Mapping the Cohesion and Synergy in Clinical Research Sites
Background and Introduction Clinical Research is a combination of many diverse and dedicated professional talents. A clinical research site usually comprises of coordinators, researchers, physicians,Expand
The value of randomized trials for efficacy in oncology: Lessons from off-label prescribing
This paper investigates the role of efficacy evidence produced in randomized controlled trials (RCTs) on demand for cancer drugs. I use the unique setting of off-label prescribing, where it isExpand
Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?
TLDR
Administrative data were more complete than trial data for hospital encounters, a key cost driver in economic analysis, and demonstrates the potential of administrative data to relieve the burden of collecting key data in cancer trials, which represents a considerable effort and expense. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
The costs of conducting clinical research.
TLDR
The time required for nontreatment trial activities is considerable, and the associated costs are substantial, according to the results of a mock phase III clinical research trial. Expand
Sensible approaches for reducing clinical trial costs
TLDR
It is suggested that it is possible to reduce substantially the cost of large-scale clinical trials without compromising the scientific validity of their results and could free billions of dollars annually for additional clinical studies. Expand
The cost of drug development: a systematic review.
TLDR
Despite three decades of research, no published estimate of the cost of developing a drug can be considered a gold standard and studies on this topic should be subjected to reasonable audit and disclosure of the drugs which authors purport to provide development cost estimates for. Expand
Assessing the Impact of Protocol Design Changes on Clinical Trial Performance
TLDR
The results of this study indicate that the number of unique procedures and the frequency of procedures per protocol have increased at the annual rate of 6.5% and 8.7%, respectively, during the time period measured, and implications for simplifying protocol designs and minimizing negative effects on study conduct performance are discussed. Expand
The price of innovation: new estimates of drug development costs.
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drugExpand
PhRMA BioResearch Monitoring Committee Perspective on Acceptable Approaches for Clinical Trial Monitoring
TLDR
The current thinking of the PhRMA BioResearch Monitoring Committee on acceptable approaches to clinical trial monitoring is provided, taking advantage of risk-based decision making and modem technological tools. Expand
Estimating the cost of new drug development: is it really 802 million dollars?
TLDR
This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues, using their published cost estimates along with information on success rates and durations from a publicly available data set, to estimate the cost per new drug between 1989 and 2002. Expand
Impediments to Clinical Research in the United States
Clinical trials are essential to the evaluation of promising scientific discoveries, but they are becoming unsustainably burdensome, threatening to deprive patients and health‐care providers of newExpand
Risk-Based Source Data Verification Approaches: Pros and Cons
TLDR
This article evaluates the FDA-supported risk-based approach to SDV and provides a proposal on how to modify the SDV process without undermining the validity and integrity of the trial data. Expand
Rapidly rising clinical trial costs worry researchers
  • R. Collier
  • Medicine
  • Canadian Medical Association Journal
  • 2009
TLDR
The cost of conducting a clinical trial for a drug is rising like mercury on a summer afternoon, a trend that researchers say is hampering the development of new medicines and is bad. Expand
...
1
2
3
...